Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.

  • 1.

    Valent P, Horny HP, Escribano L. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603625.

  • 2.

    Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). International Agency for Research on Cancer; Lyon, France; 2017.

    • Search Google Scholar
    • Export Citation
  • 3.

    Ryan RJ, Akin C, Castells M. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol 2013;26:533543.

    • Search Google Scholar
    • Export Citation
  • 4.

    Jawhar M, Schwaab J, Horny HP. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest 2016;46:392397.

    • Search Google Scholar
    • Export Citation
  • 5.

    Sanchez-Munoz L, Morgado JM, Alvarez-Twose I. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol 2016;172:5663.

    • Search Google Scholar
    • Export Citation
  • 6.

    Nagata H, Worobec AS, Oh CK. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:1056010564.

    • Search Google Scholar
    • Export Citation
  • 7.

    Schwaab J, Schnittger S, Sotlar K. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013;122:24602466.

  • 8.

    Hartmann K, Escribano L, Grattan C. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016;137:3545.

    • Search Google Scholar
    • Export Citation
  • 9.

    Escribano L, Alvarez-Twose I, Sanchez-Munoz L. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514521.

    • Search Google Scholar
    • Export Citation
  • 10.

    Lim KH, Tefferi A, Lasho TL. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:57275736.

    • Search Google Scholar
    • Export Citation
  • 11.

    Pardanani A, Lim KH, Lasho TL. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010;115:150151.

    • Search Google Scholar
    • Export Citation
  • 12.

    Alvarez-Twose I, Jara-Acevedo M, Morgado JM. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol 2016;137:168178 e161.

    • Search Google Scholar
    • Export Citation
  • 13.

    Akin C, Scott LM, Kocabas CN. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood 2007;110:23312333.

    • Search Google Scholar
    • Export Citation
  • 14.

    Pardanani A, Chen D, Abdelrahman RA. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia 2013;27:20912094.

    • Search Google Scholar
    • Export Citation
  • 15.

    Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017;140:349355.

  • 16.

    Lyons JJ, Yu X, Hughes JD. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016;48:15641569.

    • Search Google Scholar
    • Export Citation
  • 17.

    Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002;127:147152.

  • 18.

    Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226232.

    • Search Google Scholar
    • Export Citation
  • 19.

    van Anrooij B, Kluin-Nelemans JC, Safy M. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy 2016;71:15851593.

    • Search Google Scholar
    • Export Citation
  • 20.

    Gulen T, Hagglund H, Dahlen B, Nilsson G. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med 2016;279:211228.

    • Search Google Scholar
    • Export Citation
  • 21.

    Zanotti R, Bonadonna P, Bonifacio M. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica 2011;96:482484.

    • Search Google Scholar
    • Export Citation
  • 22.

    Pardanani A, Lim KH, Lasho TL. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009;114:37693772.

    • Search Google Scholar
    • Export Citation
  • 23.

    Wang SA, Hutchinson L, Tang G. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol 2013;88:219224.

    • Search Google Scholar
    • Export Citation
  • 24.

    Valent P, Sotlar K, Sperr WR. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014;25:16911700.

    • Search Google Scholar
    • Export Citation
  • 25.

    Valent P, Berger J, Cerny-Reiterer S. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol 2015;94:223231.

    • Search Google Scholar
    • Export Citation
  • 26.

    Valent P, Sotlar K, Sperr WR. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. Leuk Res 2015;39:15.

    • Search Google Scholar
    • Export Citation
  • 27.

    Georgin-Lavialle S, Lhermitte L, Dubreuil P. Mast cell leukemia. Blood 2013;121:12851295.

  • 28.

    Jawhar M, Schwaab J, Meggendorfer M. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica 2017;102:10351043.

    • Search Google Scholar
    • Export Citation
  • 29.

    Sperr WR, Jordan JH, Fiegl M. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002;128:136141.

    • Search Google Scholar
    • Export Citation
  • 30.

    Schwartz LB, Metcalfe DD, Miller JS. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987;316:16221626.

    • Search Google Scholar
    • Export Citation
  • 31.

    Sperr WR, El-Samahi A, Kundi M. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009;39:914923.

    • Search Google Scholar
    • Export Citation
  • 32.

    Aberer E, Savic S, Bretterklieber A. Disease spectrum in patients with elevated serum tryptase levels. Australas J Dermatol 2015;56:713.

  • 33.

    Caughey GH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol 2006;117:14111414.

  • 34.

    Horny HP, Sotlar K, Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology 2010;77:169180.

    • Search Google Scholar
    • Export Citation
  • 35.

    Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am J Clin Pathol 2004;121:264267.

    • Search Google Scholar
    • Export Citation
  • 36.

    Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011;24:11571168.

    • Search Google Scholar
    • Export Citation
  • 37.

    Reichard KK, Chen D, Pardanani A. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am J Clin Pathol 2015;144:493502.

    • Search Google Scholar
    • Export Citation
  • 38.

    Jordan JH, Walchshofer S, Jurecka W. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001;32:545552.

    • Search Google Scholar
    • Export Citation
  • 39.

    Horny HP, Sotlar K, Valent P. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am 2014;34:315321.

    • Search Google Scholar
    • Export Citation
  • 40.

    Teodosio C, Mayado A, Sanchez-Munoz L. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol 2015;97:4959.

    • Search Google Scholar
    • Export Citation
  • 41.

    Escribano L, Diaz Agustin B, Bravo P. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma 1999;35:227235.

    • Search Google Scholar
    • Export Citation
  • 42.

    Sotlar K, Horny HP, Simonitsch I. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:13191325.

    • Search Google Scholar
    • Export Citation
  • 43.

    Pardanani A, Kimlinger T, Reeder T. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777783.

    • Search Google Scholar
    • Export Citation
  • 44.

    Morgado JM, Sanchez-Munoz L, Teodosio CG. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. Mod Pathol 2012;25:516521.

    • Search Google Scholar
    • Export Citation
  • 45.

    Chisholm KM, Merker JD, Gotlib JR. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol 2015;143:527534.

    • Search Google Scholar
    • Export Citation
  • 46.

    Sotlar K, Cerny-Reiterer S, Petat-Dutter K. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011;24:585595.

    • Search Google Scholar
    • Export Citation
  • 47.

    Valent P, Sotlar K, Horny HP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011;52:740744.

    • Search Google Scholar
    • Export Citation
  • 48.

    Morgado JM, Perbellini O, Johnson RC. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 2013;63:780787.

    • Search Google Scholar
    • Export Citation
  • 49.

    Russano de Paiva Silva G, Tournier E, Sarian LO. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore) 2018;97:e10642.

    • Search Google Scholar
    • Export Citation
  • 50.

    Mayado A, Teodosio C, Dasilva-Freire N. Characterization of CD34(+) hematopoietic cells in systemic mastocytosis: potential role in disease dissemination. Allergy 2018;73:12941304.

    • Search Google Scholar
    • Export Citation
  • 51.

    Escribano L, Garcia Montero AC, Nunez R. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am 2006;26:535547.

    • Search Google Scholar
    • Export Citation
  • 52.

    Sanchez-Munoz L, Teodosio C, Morgado JM. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. Immunol Allergy Clin North Am 2014;34:297313.

    • Search Google Scholar
    • Export Citation
  • 53.

    Longley BJ, Tyrrell L, Lu SZ. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312314.

    • Search Google Scholar
    • Export Citation
  • 54.

    Garcia-Montero AC, Jara-Acevedo M, Teodosio C. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:23662372.

    • Search Google Scholar
    • Export Citation
  • 55.

    Sotlar K, Colak S, Bache A. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010;220:586595.

    • Search Google Scholar
    • Export Citation
  • 56.

    Tefferi A, Levine RL, Lim KH. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900904.

    • Search Google Scholar
    • Export Citation
  • 57.

    Traina F, Visconte V, Jankowska AM. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 2012;7:e43090.

    • Search Google Scholar
    • Export Citation
  • 58.

    Damaj G, Joris M, Chandesris O. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014;9:e85362.

    • Search Google Scholar
    • Export Citation
  • 59.

    Jawhar M, Schwaab J, Hausmann D. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia 2016;30:23422350.

    • Search Google Scholar
    • Export Citation
  • 60.

    Jawhar M, Schwaab J, Schnittger S. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia 2016;30:136143.

    • Search Google Scholar
    • Export Citation
  • 61.

    Pardanani AD, Lasho TL, Finke C. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. Br J Haematol 2016;175:534536.

    • Search Google Scholar
    • Export Citation
  • 62.

    Pardanani A, Lasho T, Elala Y. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol 2016;91:888893.

    • Search Google Scholar
    • Export Citation
  • 63.

    Pardanani A, Ketterling RP, Brockman SR. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:30933096.

    • Search Google Scholar
    • Export Citation
  • 64.

    Pardanani A, Brockman SR, Paternoster SF. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:30383045.

    • Search Google Scholar
    • Export Citation
  • 65.

    Bohm A, Fodinger M, Wimazal F. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007;120:192199.

    • Search Google Scholar
    • Export Citation
  • 66.

    Arock M, Sotlar K, Akin C. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia 2015;29:12231232.

    • Search Google Scholar
    • Export Citation
  • 67.

    Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011;13:180188.

    • Search Google Scholar
    • Export Citation
  • 68.

    Kristensen T, Vestergaard H, Bindslev-Jensen C. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 2014;89:493498.

    • Search Google Scholar
    • Export Citation
  • 69.

    Jara-Acevedo M, Teodosio C, Sanchez-Munoz L. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol 2015;28:11381149.

    • Search Google Scholar
    • Export Citation
  • 70.

    Kristensen T, Vestergaard H, Bindslev-Jensen C. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. Allergy 2017;72:17371743.

    • Search Google Scholar
    • Export Citation
  • 71.

    Sotlar K, Escribano L, Landt O. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737746.

    • Search Google Scholar
    • Export Citation
  • 72.

    Gotlib J, Pardanani A, Akin C. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013;121:23932401.

    • Search Google Scholar
    • Export Citation
  • 73.

    Barete S, Assous N, de Gennes C. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69:18381841.

  • 74.

    Rossini M, Zanotti R, Bonadonna P. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011;49:880885.

    • Search Google Scholar
    • Export Citation
  • 75.

    van der Veer E, van der Goot W, de Monchy JG. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012;67:431438.

    • Search Google Scholar
    • Export Citation
  • 76.

    Metcalfe DD, Pawankar R, Ackerman SJ. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 2016;9:7.

    • Search Google Scholar
    • Export Citation
  • 77.

    Morrow JD, Guzzo C, Lazarus G. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995;104:937940.

    • Search Google Scholar
    • Export Citation
  • 78.

    Oranje AP, Mulder PG, Heide R. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol 2002;27:502506.

    • Search Google Scholar
    • Export Citation
  • 79.

    Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2010;92:7376.

  • 80.

    van Doormaal JJ, van der Veer E, van Voorst Vader PC. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. Allergy 2012;67:683690.

    • Search Google Scholar
    • Export Citation
  • 81.

    Divekar R, Butterfield J. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. Allergy 2015;70:12301238.

    • Search Google Scholar
    • Export Citation
  • 82.

    Cho C, Nguyen A, Bryant KJ. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. Immun Inflamm Dis 2016;4:6469.

    • Search Google Scholar
    • Export Citation
  • 83.

    Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha. J Allergy Clin Immunol Pract 2014;2:775778.

    • Search Google Scholar
    • Export Citation
  • 84.

    Cardet JC, Akin C, Lee MJ. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14:20332045.

  • 85.

    Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979;301:465469.

  • 86.

    Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990;85:852855.

  • 87.

    Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004;350:735736.

  • 88.

    Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012;29:222223.

    • Search Google Scholar
    • Export Citation
  • 89.

    Butterfield JH. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009;88:122124.

  • 90.

    Broesby-Olsen S, Vestergaard H, Mortz CG. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy 2018;73:230238.

    • Search Google Scholar
    • Export Citation
  • 91.

    Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007;37:15471555.

    • Search Google Scholar
    • Export Citation
  • 92.

    Gulen T, Hagglund H, Dahlen B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis—a single-centre experience. Clin Exp Allergy 2014;44:121129.

    • Search Google Scholar
    • Export Citation
  • 93.

    Gorska A, Niedoszytko M, Lange M. Risk factors for anaphylaxis in patients with mastocytosis. Pol Arch Med Wewn 2015;125:4653.

  • 94.

    Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2014;133:520528.

    • Search Google Scholar
    • Export Citation
  • 95.

    Gulen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract 2017;5:12481255.

    • Search Google Scholar
    • Export Citation
  • 96.

    Niedoszytko M, Bonadonna P, Oude Elberink JN, Golden DB. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients. Immunol Allergy Clin North Am 2014;34:365381.

    • Search Google Scholar
    • Export Citation
  • 97.

    Jimenez-Rodriguez TW, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J Asthma Allergy 2018;11:121142.

    • Search Google Scholar
    • Export Citation
  • 98.

    Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy 2014;44:914920.

    • Search Google Scholar
    • Export Citation
  • 99.

    van Anrooij B, van der Veer E, de Monchy JG. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol 2013;132:125130.

    • Search Google Scholar
    • Export Citation
  • 100.

    Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003;33:12161220.

    • Search Google Scholar
    • Export Citation
  • 101.

    Bonadonna P, Perbellini O, Passalacqua G. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680686.

    • Search Google Scholar
    • Export Citation
  • 102.

    Rueff F, Przybilla B, Bilo MB. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009;124:10471054.

    • Search Google Scholar
    • Export Citation
  • 103.

    Alvarez-Twose I, Bonadonna P, Matito A. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol 2013;131:614615.

    • Search Google Scholar
    • Export Citation
  • 104.

    Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract 2015;3:350355.

    • Search Google Scholar
    • Export Citation
  • 105.

    Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008;121:519526.

    • Search Google Scholar
    • Export Citation
  • 106.

    Bonadonna P, Gonzalez-de-Olano D, Zanotti R. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474478.

    • Search Google Scholar
    • Export Citation
  • 107.

    Verburg M, Oldhoff JM, Klemans RJ. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol 2015;47:192196.

    • Search Google Scholar
    • Export Citation
  • 108.

    Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:10271032.

    • Search Google Scholar
    • Export Citation
  • 109.

    Carter MC, Robyn JA, Bressler PB. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119:15501551.

    • Search Google Scholar
    • Export Citation
  • 110.

    Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009;102:257258.

  • 111.

    Rossini M, Zanotti R, Orsolini G. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 2016;27:24112421.

    • Search Google Scholar
    • Export Citation
  • 112.

    Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997;36:393396.

    • Search Google Scholar
    • Export Citation
  • 113.

    Rossini M, Zanotti R, Viapiana O. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 2014;127:1127 e11211124.

  • 114.

    Lehmann T, Beyeler C, Lammle B. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996;35:898900.

    • Search Google Scholar
    • Export Citation
  • 115.

    Weide R, Ehlenz K, Lorenz W. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996;72:4143.

    • Search Google Scholar
    • Export Citation
  • 116.

    Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011;124:776778.

    • Search Google Scholar
    • Export Citation
  • 117.

    Orsolini G, Gavioli I, Tripi G. Denosumab for the treatment of mastocytosis-related osteoporosis: a case series. Calcif Tissue Int 2017;100:595598.

    • Search Google Scholar
    • Export Citation
  • 118.

    Kruger A, Hamann C, Brendel C. Multimodal therapy for vertebral involvement of systemic mastocytosis. Spine (Phila Pa 1976) 2009;34:E626628.

    • Search Google Scholar
    • Export Citation
  • 119.

    Gotlib J, Kluin-Nelemans HC, George TI. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016;374:25302541.

    • Search Google Scholar
    • Export Citation
  • 120.

    Chandesris MO, Damaj G, Canioni D. Midostaurin in advanced systemic mastocytosis. N Engl J Med 2016;374:26052607.

  • 121.

    DeAngelo DJ, George TI, Linder A. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 2018;32:470478.

    • Search Google Scholar
    • Export Citation
  • 122.

    Jawhar M, Schwaab J, Naumann N. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood 2017;130:137145.

    • Search Google Scholar
    • Export Citation
  • 123.

    Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ. Cladribine therapy for systemic mastocytosis. Blood 2003;102:42704276.

  • 124.

    Lim KH, Pardanani A, Butterfield JH. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009;84:790794.

    • Search Google Scholar
    • Export Citation
  • 125.

    Barete S, Lortholary O, Damaj G. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 2015;126:10091016.

    • Search Google Scholar
    • Export Citation
  • 126.

    Delaporte E, Pierard E, Wolthers BG. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995;132:479482.

    • Search Google Scholar
    • Export Citation
  • 127.

    Casassus P, Caillat-Vigneron N, Martin A. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:10901097.

    • Search Google Scholar
    • Export Citation
  • 128.

    Hauswirth AW, Simonitsch-Klupp I, Uffmann M. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004;28:249257.

    • Search Google Scholar
    • Export Citation
  • 129.

    Simon J, Lortholary O, Caillat-Vigneron N. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 2004;52:294299.

    • Search Google Scholar
    • Export Citation
  • 130.

    Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:11151124.

    • Search Google Scholar
    • Export Citation
  • 131.

    Akin C, Brockow K, D'Ambrosio C. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003;31:686692.

    • Search Google Scholar
    • Export Citation
  • 132.

    Akin C, Fumo G, Yavuz AS. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:32223225.

    • Search Google Scholar
    • Export Citation
  • 133.

    Zhang LY, Smith ML, Schultheis B. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373378.

    • Search Google Scholar
    • Export Citation
  • 134.

    Heinrich MC, Joensuu H, Demetri GD. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:27172725.

    • Search Google Scholar
    • Export Citation
  • 135.

    Vega-Ruiz A, Cortes JE, Sever M. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009;33:14811484.

    • Search Google Scholar
    • Export Citation
  • 136.

    Mital A, Piskorz A, Lewandowski K. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011;86:531535.

    • Search Google Scholar
    • Export Citation
  • 137.

    Alvarez-Twose I, Matito A, Morgado JM. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget 2017;8:6895068963.

    • Search Google Scholar
    • Export Citation
  • 138.

    Przepiorka D, Giralt S, Khouri I. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998;57:2428.

    • Search Google Scholar
    • Export Citation
  • 139.

    Nakamura R, Chakrabarti S, Akin C. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006;37:353358.

    • Search Google Scholar
    • Export Citation
  • 140.

    Ustun C, Reiter A, Scott BL. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014;32:32643274.

  • 141.

    Ustun C, Gotlib J, Popat U. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant 2016;22:13481356.

    • Search Google Scholar
    • Export Citation
  • 142.

    Valent P, Akin C, Sperr WR. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635641.

    • Search Google Scholar
    • Export Citation
  • 143.

    Matito A, Morgado JM, Alvarez-Twose I. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One 2013;8:e76116.

    • Search Google Scholar
    • Export Citation
  • 144.

    Erben P, Schwaab J, Metzgeroth G. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014;93:8188.

    • Search Google Scholar
    • Export Citation
  • 145.

    Hoermann G, Gleixner KV, Dinu GE. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy 2014;69:810813.

    • Search Google Scholar
    • Export Citation
  • 146.

    Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 2013;121:30853094.

    • Search Google Scholar
    • Export Citation
  • 147.

    Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology 2014;120:753759.

  • 148.

    Hermans MAW, Arends NJT, Gerth van Wijk R. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol 2017;119:304309.

    • Search Google Scholar
    • Export Citation
  • 149.

    Matito A, Morgado JM, Sanchez-Lopez P. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol 2015;167:4756.

    • Search Google Scholar
    • Export Citation
  • 150.

    Guyer AC, Saff RR, Conroy M. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. J Allergy Clin Immunol Pract 2015;3:94100.

    • Search Google Scholar
    • Export Citation
  • 151.

    Woidacki K, Zenclussen AC, Siebenhaar F. Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome? Front Immunol 2014;5:231.

    • Search Google Scholar
    • Export Citation
  • 152.

    Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. Obstet Gynecol 2000;95:391395.

  • 153.

    Ciach K, Niedoszytko M, Abacjew-Chmylko A. Pregnancy and delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). PLoS One 2016;11:e0146924.

    • Search Google Scholar
    • Export Citation
  • 154.

    Matito A, Alvarez-Twose I, Morgado JM. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol 2011;156:104111.

    • Search Google Scholar
    • Export Citation
  • 155.

    Ulbrich F, Engelstadter H, Wittau N, Steinmann D. Anaesthetic management of emergency caesarean section in a parturient with systemic mastocytosis. Int J Obstet Anesth 2013;22:243246.

    • Search Google Scholar
    • Export Citation
  • 156.

    Lei D, Akin C, Kovalszki A. Management of mastocytosis in pregnancy: a review. J Allergy Clin Immunol Pract 2017;5:12171223.

All Time Past Year Past 30 Days
Abstract Views 5 0 0
Full Text Views 3418 2265 210
PDF Downloads 1549 1057 138
EPUB Downloads 0 0 0